Новости


IPEC Europe разработало и опубликувало руководство по формализированной оценке рисков для вспомогательных веществ - „HOW-TO” Guide for Risk Assessment

13.04.2016 13:13
  • IPEC Europe разработало и опубликувало руководство по формализированной оценке рисков для вспомогательных веществ - „HOW-TO” Guide for Risk Assessment

IPEC Europe Publishes „HOW-TO” Guide for Risk Assessment

21 March 2016 marked the date on which Manufacturing Authorisation Holders (MAHs, also known as pharmaceutical product manufacturers) needed to be compliant with the “Guidelines of 19 March 2015 on the formalised risk assessment for ascertaining the appropriate good manufacturing practice for excipients of medicinal products for human use”. IPEC Europe has developed and published a 36-pages "How-to" documentto help explain how a company might perform a risk assessment to determine the appropriate GMPs necessary for each excipient they use in drug products.

 

Whereas MAHs may use this risk assessment strategy to determine if their excipient suppliers meet the GMP requirements they define, excipient supplier may use it to understand how their customers (MAHs) establish GMP requirements for each excipient, thus allowing the excipient supplier to anticipate and provide support as applicable.

The document frequently refers to the original European Union Guideline, but does not parallel the Guidelines in its organization. It is comprised of the following sections:

  1. Introduction
  2. Preamble
  3. The risk assessment process
    (Especially detailed and useful for those who may require a better understanding and instructions for how one might assess risk. It highlights the need to consider not only risks inherent to the excipient, but also risks from excipients suppliers and risk associated with the end used application)
  4. Risk mitigation activity including communication with the suppliers
  5. Residual risks resolution
  6. Triggers for risk review

Annexes which provide examples of a Process Flow Diagram, General Documentation Package or Compliance Declaration, Suitability of Risk Assessment tools, Formalised Excipient Risk Assessment References and Examples of risk scoring, have been included.

IPEC Europe notes that the EU Guidelines do not introduce any new requirements for GMP or Good Distribution Practice (GDP) for excipient suppliers or distributors who are already compliant with appropriate standards, such as the IPEC-PQG GMP Guide, EXCiPACT GMP and GDP standards or the NSF/IPEC/ANSI-363 2014 US national standard.

Source:

IPEC Americas: Insider

IPEC Europe: How-to document

 

Источник информации: www.gmp-publishing.com

Новости

подробнее

Контакты

Офис в Украине

Адрес: 04116, Украина, г. Киев,
ул. Шолуденка 3, офисный центр «Кубик», оф. 210
E-mail: office@biosciense.co.uk
моб.: + 38 (067) 447 19 85



Форма обратной связи